Company Description
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer.
The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors.
PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Country | Israel |
| Founded | 2008 |
| IPO Date | Jun 26, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Dikla Czaczkes Akselbrad |
Contact Details
Address: 18 Hasivim Street Petah Tikva, 4959376 Israel | |
| Phone | 972 7 4719 5700 |
| Website | polypid.com |
Stock Details
| Ticker Symbol | PYPD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001611842 |
| CUSIP Number | M8001Q118 |
| ISIN Number | IL0011326795 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dalit Hazan | Deputy Chief Executive Officer and Executive Vice President of Research & Development, Clinical and Regulatory Affairs |
| Dikla Czaczkes Akselbrad | Chief Executive Officer and Director |
| Jonny Missulawin | Chief Financial Officer |
| Ori Warshavsky | Chief Operating Officer - US |
| Maria Rubin | Executive Vice President of Operations |
| Tal Vilnai | General Counsel and Corporate Secretary |
| Rivi Lev-ari | Vice President of Human Resource |
| Dr. Jean-Marc Hagai Pharm.D. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2025 | 6-K | Report of foreign issuer |
| Aug 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 13, 2025 | SCHEDULE 13G/A | Filing |
| Aug 13, 2025 | 6-K | Report of foreign issuer |
| Aug 12, 2025 | 6-K | Report of foreign issuer |
| Aug 6, 2025 | EFFECT | Notice of Effectiveness |
| Jul 29, 2025 | SCHEDULE 13G | Filing |
| Jul 29, 2025 | F-3 | Filing |
| Jul 15, 2025 | 6-K | Report of foreign issuer |
| Jun 25, 2025 | 6-K | Report of foreign issuer |